Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia.
Hepatic Steatosis
Non-Obese
Prostate Hyperplasia
Journal
Journal of Korean medical science
ISSN: 1598-6357
Titre abrégé: J Korean Med Sci
Pays: Korea (South)
ID NLM: 8703518
Informations de publication
Date de publication:
08 Jun 2020
08 Jun 2020
Historique:
received:
18
12
2019
accepted:
31
03
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
11
3
2021
Statut:
epublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is associated with a wide spectrum of metabolic abnormalities. This study aimed to evaluate whether NAFLD is associated with benign prostatic hyperplasia (BPH) independent of other risk factors. A total of 3,508 subjects who underwent prostate and hepatic ultrasonography were enrolled. NAFLD was diagnosed and graded by ultrasonographic findings. BPH was defined by total prostate volume. The prevalence of BPH was significantly increased according to NAFLD severity ( NAFLD is associated with an increased risk of BPH regardless of metabolic syndrome, especially in non-obese subjects. An incrementally increased risk of BPH according to NAFLD severity is prominent in non-obese subjects with NAFLD. Thus, physicians caring for non-obese patients with NAFLD may consider assessing the risk of BPH and associated urologic conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) is associated with a wide spectrum of metabolic abnormalities. This study aimed to evaluate whether NAFLD is associated with benign prostatic hyperplasia (BPH) independent of other risk factors.
METHODS
METHODS
A total of 3,508 subjects who underwent prostate and hepatic ultrasonography were enrolled. NAFLD was diagnosed and graded by ultrasonographic findings. BPH was defined by total prostate volume.
RESULTS
RESULTS
The prevalence of BPH was significantly increased according to NAFLD severity (
CONCLUSION
CONCLUSIONS
NAFLD is associated with an increased risk of BPH regardless of metabolic syndrome, especially in non-obese subjects. An incrementally increased risk of BPH according to NAFLD severity is prominent in non-obese subjects with NAFLD. Thus, physicians caring for non-obese patients with NAFLD may consider assessing the risk of BPH and associated urologic conditions.
Identifiants
pubmed: 32508064
pii: 35.e164
doi: 10.3346/jkms.2020.35.e164
pmc: PMC7279945
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e164Informations de copyright
© 2020 The Korean Academy of Medical Sciences.
Déclaration de conflit d'intérêts
The authors have no potential conflicts of interest to disclose.
Références
Br J Urol. 1966 Feb;38(1):18-23
pubmed: 4143704
Obes Rev. 2002 Nov;3(4):303-8
pubmed: 12458975
Differentiation. 2011 Nov-Dec;82(4-5):184-99
pubmed: 21620560
N Engl J Med. 2002 Apr 18;346(16):1221-31
pubmed: 11961152
Urology. 1995 Sep;46(3 Suppl A):23-5
pubmed: 7544513
Andrology. 2018 Sep;6(5):737-741
pubmed: 29858538
Eur Urol. 2001 Feb;39(2):151-8
pubmed: 11223674
World J Urol. 2015 May;33(5):743-51
pubmed: 25189458
Am J Epidemiol. 2010 Mar 1;171(5):571-82
pubmed: 20142396
Clin Dev Immunol. 2013;2013:926937
pubmed: 23956762
J Urol. 1984 Sep;132(3):474-9
pubmed: 6206240
Clin Mol Hepatol. 2013 Dec;19(4):325-48
pubmed: 24459637
J Urol. 2010 Sep;184(3):1040-4
pubmed: 20643424
Prostate. 2004 Oct 1;61(2):124-31
pubmed: 15305335
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
J Urol. 2002 Aug;168(2):599-604
pubmed: 12131317
Andrology. 2016 May;4(3):404-11
pubmed: 27089546
Ann Hepatol. 2012 Jul-Aug;11(4):440-9
pubmed: 22700625
Prostate Cancer Prostatic Dis. 2013 Mar;16(1):101-6
pubmed: 23165431
World J Gastroenterol. 2014 Dec 28;20(48):18070-91
pubmed: 25561778
Eur Urol. 2013 Jun;63(6):1115-21
pubmed: 23541458
J Urol. 1999 Jan;161(1):122-7
pubmed: 10037383
Int J Androl. 2010 Jun 1;33(3):475-88
pubmed: 19508330
Diabetes. 2001 Aug;50(8):1844-50
pubmed: 11473047
Hepatology. 2004 Dec;40(6):1387-95
pubmed: 15565570
Mol Cell Endocrinol. 2004 Feb 27;215(1-2):135-41
pubmed: 15026186
Atherosclerosis. 2013 Apr;227(2):398-403
pubmed: 23390894
Prostate. 2011 Jul;71(10):1097-107
pubmed: 21557274
Clin Gastroenterol Hepatol. 2017 Apr;15(4):474-485
pubmed: 27581063
BJU Int. 2015 Jan;115(1):24-31
pubmed: 24602293
Dig Dis. 2016;34 Suppl 1:11-8
pubmed: 27548822
Hepatology. 2005 Nov;42(5):987-1000
pubmed: 16250043
Clin Mol Hepatol. 2016 Mar;22(1):146-51
pubmed: 27044765
BJU Int. 2019 Aug;124(2):329-335
pubmed: 30900792
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Prostate Cancer Prostatic Dis. 2012 Sep;15(3):265-72
pubmed: 22183774
Gastroenterology. 2012 Jun;142(7):1592-609
pubmed: 22656328
Nat Rev Urol. 2011 Jan;8(1):29-41
pubmed: 21228820
Dig Dis Sci. 2012 Jul;57(7):1932-41
pubmed: 22427130
J Endocrinol Invest. 2014 Apr;37(4):313-22
pubmed: 24458832
Gastroenterology. 2002 Sep;123(3):745-50
pubmed: 12198701
Liver Int. 2018 Nov;38(11):2051-2059
pubmed: 29517842
Prostate. 2016 Dec;76(16):1528-1535
pubmed: 27458062
Invest Urol. 1978 Jan;15(4):340-5
pubmed: 75197
Hepatology. 2011 Sep 2;54(3):1082-1090
pubmed: 21618575
Urol Clin North Am. 1995 May;22(2):237-46
pubmed: 7539172